Arca Biopharma Inc (NASDAQ:ABIO) down -13.91% to close at the price of $13. The stock has a market capitalization of $16.51 Million however its outstanding shares are 1.27 Million. The company’s beta value stood at 0.89.
Analysts are expecting average earnings estimates of $-1.8 for the current quarter based on the opinion of 1 analysts, relating to high earnings per share estimates of $-1.8 and low estimates of $-1.8, however Arca Biopharma Inc (NASDAQ:ABIO) reported $-2.7 earnings per share for the same quarter last year.
Taking a broader look at the analyst consensus, brokerage firms have a price target of $16.2 on Arca Biopharma Inc (NASDAQ:ABIO). Brokerage firms on the street have price targets on the name ranging from $16.2 to $16.2 based on 1 opinions.
Arca Biopharma Inc (NASDAQ:ABIO) as of current trade, has shown weekly performance of 19.27% which was maintained at 119.59% in one month period. Year to date performance remained at 116.56%. During the past three months the stock gain 95.14%, however six months performance of the stock remained at -8.2%. Arca Biopharma Inc (NASDAQ:ABIO)’s price sits 73.92% above from its SMA 50 of $7.51 and 41.69% far from the SMA 200 which is at $8.26.
Currently Arca Biopharma Inc (NASDAQ:ABIO)’s shares owned by insiders are 0.83%, whereas shares owned by institutional owners are 10.9%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0%.
The stock is trading -43.58% away from its 52 week high of $23.04 and 175.13% far from the stock’s low point over the past 52 weeks, which was $4.72.
The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Arca Biopharma Inc (NASDAQ:ABIO)’s price to earnings ratio stood at 0. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.
The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Arca Biopharma Inc (NASDAQ:ABIO) has a current PEG of 0. Arca Biopharma Inc (NASDAQ:ABIO)’s price to sales ratio for trailing twelve month stands at 0, whereas its price to book ratio for the most recent quarters is at 0.09. However the company’s price to cash per share for most recent quarter stands at 0. Its price to free cash flow for trailing twelve months is 0.